Tumor profiling tests to guide adjuvant chemotherapy decision in early breast cancer

28 Ιανουαρίου, 2025

Tumor profiling tests to guide adjuvant chemotherapy decision in early breast cancer

NICE diagnostics guidance – evaluation of effectiveness and efficiency

The NICE (National Institute for Health and Care Excellence) diagnostics guidance DG58 gives
evidence-based recommendations to guide treatment decisions and evaluate the efficiency
and cost-effectiveness of products and services in the health system of England and Wales.

Use of multigene assays (MGAs) for tumour profiling

Tumour profiling by MGAs could be used to guide decisions on adjuvant chemotherapy by
identifying patients who:

may not benefit from adjuvant chemotherapy and avoid unnecessary treatment.
who would actually benefit from chemotherapy, although they have a low risk of disease recurrence due to clinical factors.

This summary of NICE diagnostics guidance ‘Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer’ (DG58) is promotional material. NICE has checked the accuracy of the content in this leaflet specifically relating to the NICE guidance. NICE is independent of any company or product advertised.

Economic value of multigene assays MGAs

Economic modelling suggests that Oncotype DX®, EndoPredict® and Prosigna® are cost-effective compared with standard care in postmenopausal women. All 3 tests had ICERs < £ 20,000 per QALY gained when compared to not using tumour profiling tests.

MammaPrint® is likely to be less clinically effective and costs more than standard care.